Vanguard Capital Management LLC has disclosed an increase in its ownership stake in Procept BioRobotics Corp. The recent filing reveals that Vanguard now holds approximately 4.96% of the company, amounting to over 2.8 million shares. This development is significant as it underscores Vanguard's growing influence within the surgical and medical instruments industry.

Procept BioRobotics, based in San Jose, California, specializes in surgical and medical instruments and apparatus. The company has been making strides in its field, and Vanguard's increased investment could be a vote of confidence in its future prospects.

The SEC filing, dated October 30, 2026, is an amendment to the Schedule 13G, which reports beneficial ownership of securities. According to the filing, Vanguard Capital Management has sole voting power over 433,130 shares and sole dispositive power over 2,845,781 shares. This indicates that Vanguard has significant control over its investment in Procept BioRobotics.

Vanguard's filing notes, "This Schedule 13G reflects the securities beneficially owned, or deemed to be beneficially owned, by Vanguard Capital Management LLC and the following affiliates of Vanguard Capital Management LLC or business divisions of such affiliates." This includes various Vanguard funds and affiliates that exercise dispositive and voting power over the shares.

The filing may impact not only Procept BioRobotics but also its competitors in the surgical and medical instruments sector. As Vanguard increases its stake, other companies may need to evaluate their strategies and market positions in response to this significant investment.

Looking ahead, the filing does not specify what actions Vanguard Capital Management may take next regarding its investment in Procept BioRobotics. However, the increase in ownership suggests a potential long-term commitment to the company.